Positive News SentimentPositive NewsNASDAQ:CADL Candel Therapeutics (CADL) Stock Price, News & Analysis $5.70 +0.02 (+0.35%) (As of 10/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Candel Therapeutics Stock (NASDAQ:CADL) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Candel Therapeutics alerts:Sign Up Key Stats Today's Range$5.54▼$5.7450-Day Range$5.25▼$7.7652-Week Range$0.66▼$14.30Volume143,319 shsAverage Volume1.94 million shsMarket Capitalization$169.46 millionP/E RatioN/ADividend YieldN/APrice Target$11.00Consensus RatingBuy Company OverviewCandel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. Candel Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks55th Percentile Overall ScoreCADL MarketRank™: Candel Therapeutics scored higher than 55% of companies evaluated by MarketBeat, and ranked 497th out of 1,001 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCandel Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageCandel Therapeutics has received no research coverage in the past 90 days.Read more about Candel Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Candel Therapeutics is -3.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Candel Therapeutics is -3.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCandel Therapeutics has a P/B Ratio of 12.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Candel Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted8.21% of the float of Candel Therapeutics has been sold short.Short Interest Ratio / Days to CoverCandel Therapeutics has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Candel Therapeutics has recently decreased by 5.92%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCandel Therapeutics does not currently pay a dividend.Dividend GrowthCandel Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.21% of the float of Candel Therapeutics has been sold short.Short Interest Ratio / Days to CoverCandel Therapeutics has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in Candel Therapeutics has recently decreased by 5.92%, indicating that investor sentiment is improving significantly. News and Social Media2.6 / 5News SentimentN/A News SentimentCandel Therapeutics has a news sentiment score of 1.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Candel Therapeutics this week, compared to 1 article on an average week. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Candel Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $193,380.00 in company stock.Percentage Held by Insiders41.60% of the stock of Candel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 13.93% of the stock of Candel Therapeutics is held by institutions.Read more about Candel Therapeutics' insider trading history. Receive CADL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Candel Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address CADL Stock News HeadlinesInsider Selling: Candel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Sells 15,000 Shares of StockOctober 16, 2024 | insidertrades.comCandel Therapeutics, Inc. (NASDAQ:CADL) Major Shareholder Estuardo Aguilar-Cordova Sells 1,800 SharesOctober 4, 2024 | insidertrades.comWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonOctober 24, 2024 | Porter & Company (Ad)Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual MeetingOctober 4, 2024 | globenewswire.comCandel Therapeutics, Inc. (NASDAQ:CADL) most popular amongst individual investors who own 48%, insiders hold 30%September 13, 2024 | finance.yahoo.comCandel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | finance.yahoo.comCADL Sep 2024 9.000 call (CADL240920C00009000)August 30, 2024 | finance.yahoo.comCandel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate HighlightsAugust 13, 2024 | finance.yahoo.comSee More Headlines CADL Stock Analysis - Frequently Asked Questions How have CADL shares performed this year? Candel Therapeutics' stock was trading at $1.47 at the start of the year. Since then, CADL stock has increased by 287.4% and is now trading at $5.6950. View the best growth stocks for 2024 here. How were Candel Therapeutics' earnings last quarter? Candel Therapeutics, Inc. (NASDAQ:CADL) announced its quarterly earnings data on Tuesday, August, 13th. The company reported ($0.74) earnings per share for the quarter. When did Candel Therapeutics IPO? Candel Therapeutics (CADL) raised $72 million in an IPO on Tuesday, July 27th 2021. The company issued 9,000,000 shares at $8.00 per share. Jefferies, Credit Suisse, BMO Capital Markets and UBS Investment Bank served as the underwriters for the IPO. How do I buy shares of Candel Therapeutics? Shares of CADL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Candel Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Candel Therapeutics investors own include Advanced Micro Devices (AMD), Netflix (NFLX), NVIDIA (NVDA), Tesla (TSLA), Alphabet (GOOG), Meta Platforms (META) and Visa (V). Company Calendar Last Earnings8/13/2024Today10/23/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CADL CUSIPN/A CIK1841387 Webwww.candeltx.com Phone617-916-5445FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+93.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-37,940,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-629.29% Return on Assets-134.23% Debt Debt-to-Equity Ratio1.66 Current Ratio1.62 Quick Ratio1.62 Sales & Book Value Annual Sales$120,000.00 Price / Sales1,412.17 Cash FlowN/A Price / Cash FlowN/A Book Value$0.44 per share Price / Book12.94Miscellaneous Outstanding Shares29,756,000Free Float18,738,000Market Cap$169.46 million OptionableOptionable Beta-0.95 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report This page (NASDAQ:CADL) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Candel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Candel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.